Logo
Euro Gen GHRP 6, 5mg

Euro Gen GHRP 6, 5mg

Euro-Gen

Research chemical / peptide reagent
  • Supplied and labelled as a research Use Only peptide reagent, not as a medicinal product, medical device, cosmetic or food.
  • Not authorised or licensed by the MHRA, EMA, FDA or other regulatory authorities for any therapeutic indication.
  • Use governed by general chemical and biological safety regulations and institutional policies applicable to laboratory reagents in the relevant jurisdiction.
  • Researchers and institutions are responsible for ensuring that experimental use complies with local laws, ethics approvals and applicable anti Doping and professional practice codes.
Growth hormone-releasing hexapeptide (GHRP-6) for in vitro research

Description

Euro-Gen GHRP-6, 5mg is a synthetic research peptide supplied as a lyophilised powder in a sealed vial, intended strictly for in vitro testing and laboratory research. GHRP-6 (Growth Hormone-Releasing Peptide-6) is a hexapeptide growth hormone secretagogue and synthetic ghrelin receptor (GHSR) agonist with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. It has been extensively studied in preclinical and early clinical research for its ability to stimulate growth hormone (GH) release and to modulate appetite, body composition, metabolism, cardiovascular function and tissue repair. The Euro-Gen preparation is marketed as a high-purity, research-grade GHRP-6 reagent and is clearly labelled as not for human or veterinary administration and not as a medicinal product.

Bnefits

  • Provides a defined 5 mg quantity of synthetic GHRP-6 hexapeptide per vial for reproducible in vitro and preclinical studies.
  • GHRP-6 is a well-characterised growth hormone secretagogue and ghrelin receptor agonist, widely used as a tool compound to investigate GH/IGF-1 axis regulation.
  • Enables research into mechanisms underlying muscle growth, recovery, appetite regulation, body composition, glucose metabolism and cardiovascular function in experimental models.
  • Useful for dissecting ghrelin receptor signalling, phosphatidylinositol (PI) turnover and downstream endocrine responses in cell culture and animal models.
  • Supplied as a lyophilised, high-purity (typically ≥98–99% by HPLC, depending on batch) peptide suitable for analytical, biochemical and cell-based assays.
  • Clearly designated as research-use-only, facilitating appropriate segregation from regulated medicines and preventing inadvertent therapeutic or performance-enhancement use.

Indications

  • No approved therapeutic indications; Euro-Gen GHRP-6, 5mg is not licensed as a medicine or medical device.
  • Intended exclusively for in vitro and preclinical laboratory research on growth hormone secretagogues and ghrelin receptor agonists.
  • Suitable for research on GH/IGF-1 axis modulation, body composition, appetite regulation, tissue repair, cardioprotection and metabolic regulation in appropriate experimental systems.
  • May be used in cell culture, ex vivo preparations and ethically approved animal models as a research reagent under institutional and regulatory oversight.
  • Not for injection, ingestion, inhalation, topical application or any other administration to humans or animals.

Composition

  • Active research ingredient: GHRP-6 (Growth Hormone-Releasing Peptide-6).
  • Peptide sequence (one-letter code): His-D-Trp-Ala-Trp-D-Phe-Lys-NH2.
  • Empirical molecular formula: C46H56N12O6.
  • Molecular weight: approximately 873.0 g/mol.
  • CAS Registry Number: 87616-84-0.
  • Synonyms: Growth Hormone-Releasing Hexapeptide; [His1, Lys6]-GHRP; HWAWFK-NH2; SK&F 110679.
  • Supplied as a lyophilised (freeze-dried) peptide powder; any minor lyophilisation excipients (e.g. mannitol, salts) are typically batch-dependent and specified in technical documentation rather than retail listing.
  • No diluent, solvent or bacteriostatic agent is supplied in the vial; these must be provided separately by the laboratory if reconstitution is required.

Formulation

  • Lyophilised synthetic hexapeptide GHRP-6 in a sterile, sealed glass vial containing a nominal 5 mg of active peptide.
  • Research-grade purity (vendor-claimed high purity, typically ≥98–99% by HPLC) suitable for in vitro and preclinical applications.
  • Designed for reconstitution with appropriate sterile laboratory-grade diluents (e.g. bacteriostatic water, sterile saline or assay buffer) following institutional SOPs.
  • Formulated and labelled exclusively as a research reagent and not as a pharmaceutical dosage form for human or veterinary therapy.

Packaging

  • Single 5 mg GHRP-6 lyophilised peptide vial with rubber stopper and crimped cap, labelled with product name (Euro-Gen GHRP-6, 5mg), brand and research-use-only designation.
  • Outer secondary packaging (e.g. cardboard carton or padded mailer) used by Express Peptides and Derma Filler Ltd to protect vials during shipping.
  • Accompanying online product pages describe intended use as a research peptide, basic handling/storage guidance, and pricing; no patient information leaflet is provided because the product is not intended for therapeutic use.

Usage

  • For in vitro testing and laboratory research only; to be handled exclusively by suitably qualified and authorised personnel in an appropriate laboratory environment.
  • Any administration to humans or animals (injection, ingestion, inhalation, topical or otherwise) is strictly prohibited and outside the product’s intended purpose.
  • Before use, visually inspect the vial for integrity and appearance of the lyophilised cake; do not use if the vial is cracked, the seal compromised or the contents show visible signs of moisture or contamination.
  • Reconstitute the lyophilised peptide with an appropriate sterile, laboratory-grade diluent according to your institution’s SOPs and the requirements of the planned experiment (e.g. target concentration, buffer composition and pH).
  • Use aseptic technique during reconstitution and when withdrawing aliquots to minimise contamination and maintain experimental reliability.
  • Label reconstituted solutions with compound name, concentration, diluent, date of reconstitution and operator initials, and record the batch/lot number for traceability.
  • Store reconstituted solutions as per laboratory guidelines (e.g. in aliquots at 2–8 °C for short-term use or ≤ −20 °C for longer-term use) and avoid repeated freeze–thaw cycles to reduce peptide degradation.
  • Dispose of any unused peptide, reconstituted solutions, vials, needles, syringes and contaminated materials as chemical/biological laboratory waste in accordance with institutional policies and local regulations.

Contraindications

  • Use in humans or animals for therapeutic, enhancement or cosmetic purposes is contraindicated and explicitly outside the stated research-only purpose.
  • Should not be used as a substitute for licensed growth hormone therapies, GHRH analogues or other approved endocrine treatments.
  • Not suitable for laboratories without appropriate facilities, biosafety procedures, PPE and waste-disposal systems for handling synthetic peptides.
  • Personnel with known hypersensitivity to peptides or any excipients should avoid direct handling and follow occupational health guidance.
  • Not to be used for doping, bodybuilding or athletic performance enhancement, nor for any purpose intended to circumvent anti-doping or medical regulations.

Adverse Effects

  • No formal adverse-effect profile exists for this commercial preparation in humans or animals because it is not intended for administration.
  • Accidental laboratory exposure (e.g. skin or eye contact, inhalation of dust/aerosol or inadvertent ingestion) may cause non-specific irritation or sensitisation; affected individuals should follow standard lab first-aid procedures and seek medical evaluation if symptoms persist.
  • Unauthorised self-administration or off-label clinical use of research-grade GHRP-6 may carry significant risks, including endocrine disruption, altered glucose metabolism, changes in blood pressure, oedema, joint pain or other systemic effects, in addition to sterility and contamination concerns; such practices are strongly discouraged.
  • Laboratory personnel should consult institutional risk assessments for peptide handling, use appropriate PPE (gloves, eye protection, lab coat) and adhere to good laboratory practice to minimise exposure.

Storage Conditions

  • Store unopened vials in a cool, dry place protected from direct light and moisture; many laboratories keep lyophilised peptides refrigerated (2–8 °C) or frozen (≤ −20 °C) in line with internal SOPs.
  • Avoid prolonged exposure to elevated temperatures and repeated temperature cycling; do not use if the vial or contents appear compromised.
  • After reconstitution, store solutions according to institutional guidelines (e.g. aliquoted and stored at 2–8 °C for short term or ≤ −20 °C for longer term) and minimise freeze–thaw cycles.
  • Keep vials and reconstituted solutions out of reach of unauthorised personnel and clearly segregated from medicinal products, foodstuffs and cosmetics.
  • Dispose of expired or compromised material as laboratory waste in compliance with local regulations and institutional policies.

Duration

Not applicable. Euro-Gen GHRP-6, 5mg has no authorised therapeutic use, dosing schedule or treatment duration; any clinical or performance-enhancement use would be outside its intended research-only scope.

Onset

Not applicable to clinical outcomes. In experimental models, any observed effects of GHRP-6 on GH secretion, appetite, body composition or tissue function depend on the specific in vitro or in vivo protocol, dosage, timing and model system, and cannot be extrapolated directly to human therapeutic onset or efficacy.

Browse more Research chemical / peptide reagent

Top Treatments

Top Cities in the UK